Rapport Therapeutics, Inc. Common Stock (RAPP) EV/EBIT: History & Chart

Rapport Therapeutics, Inc. Common Stock(RAPP)

Biotechnology · Boston, MA

$30.82-1.37 (-4.26%)

Delayed quote: Oct 6, 2026, 1:00 PM EDT

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Boston, MA

84 employees

www.rapportrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Abraham N. Ceesay

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Rapport Therapeutics, Inc. Common Stock (RAPP)	$1.47B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.48B	N/A	N/A	N/A	N/A
Certara, Inc. (CERT)vs ›	$1.46B	206.20x	79.44x	108.81x	130.77x
Healthcare Services Group, Inc. (HCSG)vs ›	$1.46B	10.03x	25.95x	23.59x	24.10x
Phibro Animal Health Corporation (PAHC)vs ›	$1.49B	11.19x	15.08x	17.83x	16.60x
Eton Pharmaceuticals, Inc. (ETON)vs ›	$1.50B	91.90x	402.45x	215.28x	215.28x
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.44B	N/A	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.44B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.44B	N/A	5.99x	5.99x	5.99x
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	11.64x	36.76x	36.76x	36.50x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Rapport Therapeutics, Inc. Common Stock (RAPP)

$1.47B

N/A

GH Research PLC (GHRS)vs ›

$1.48B

N/A

Certara, Inc. (CERT)vs ›

$1.46B